Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide, MAPK Inhibitors, and Chemotherapy for Stage 4/M Neuroblastoma
NCT06933394Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2025
- Primary completion
- May 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in neuroblastoma, sponsored by Sun Yat-sen Memorial Hospital. Started May 2025; status: recruiting.
02
Drugs
trametinib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06933394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933394.